In a significant move that promises to redefine the landscape of diabetes technology, Insulet Corporation has unveiled a groundbreaking automated insulin delivery (AID) system designed specifically for the Type 2 diabetes population. During the American Diabetes Association’s (ADA) recent Scientific Sessions, company leadership described the system as a departure from traditional industry standards—a “fully closed-loop” solution that eliminates the cognitive burden of mealtime insulin dosing and manual titration.
By removing the requirement for patients to count carbohydrates or initiate bolus injections, Insulet aims to lower the barriers to entry for insulin therapy, potentially transforming how millions of individuals manage their condition.
The Core Innovation: Removing the "Bolus Button"
For decades, the standard for insulin pump therapy has been a semi-automated model: the user tells the device how many carbohydrates they are eating, and the system delivers a corresponding dose of insulin. While effective, this process is mentally taxing and prone to human error.
Insulet’s new system represents a radical shift. Chief Medical Officer Dr. Trang Ly emphasized that the company’s approach is fundamentally different from the current technologies offered by competitors like Medtronic and Tandem Diabetes Care.
"With our system, there’s no bolusing at all. There’s actually no bolus button," Dr. Ly explained. "It’s completely different to what others are working on. There are no settings for anyone to enter."
In this "fully closed-loop" model, the system manages insulin delivery entirely on its own. Physicians are not required to program complex starting settings, and dose titration—a traditionally manual, time-consuming process for doctors—is handled automatically by the system’s algorithm. This design choice is aimed squarely at the Type 2 diabetes demographic, where clinical complexity and the fear of hypoglycemia often lead to the delayed adoption of insulin therapy.
Chronology of Clinical Development
The path to this breakthrough has been a deliberate, step-by-step clinical evolution. Insulet has utilized a series of "Evolution" trials to stress-test their algorithms and ensure patient safety and efficacy before moving toward commercialization.
- March 2024: Insulet first introduced the concept and initial data at a major diabetes conference, signaling their intent to capture the Type 2 market with a simplified, fully autonomous device.
- Evolution 2 Study: This phase served as the foundational test for the system’s core algorithm, confirming that the automated logic could safely regulate blood glucose levels.
- June 2024 (ADA Scientific Sessions): Insulet presented the results of the "Evolution 3" study. This trial shifted focus toward real-world application, specifically testing the system’s "starting conditions" and the effectiveness of its auto-titration capabilities.
- The Evolve Trial (Upcoming): With the success of the Evolution 3 data, Insulet is now preparing for a pivotal, randomized, controlled trial involving approximately 300 participants. This study will compare standard therapy against the fully closed-loop system, with results expected in 2025.
- 2028 Target: Insulet has signaled a projected commercial launch for this revolutionary system in 2028, pending the successful completion of the Evolve trial and subsequent regulatory approvals.
Supporting Data: Evolution 3 Results
The Evolution 3 study, a 36-person trial, provides compelling evidence that the system can handle a diverse range of insulin needs without the user having to intervene. The cohort included adults with Type 2 diabetes, most of whom were transitioning from multiple daily injections (MDI), while others were moving from traditional pumps or basal-only regimens.
Key Performance Metrics:
- Time in Range (TIR): Participants experienced a significant improvement in their Time in Range—the gold-standard metric for glucose control—rising from 51% at the baseline to 64% during the study.
- Insulin Efficiency: The system demonstrated high efficiency in total daily insulin (TDI) requirements, which decreased from an average of 86 units to 58 units.
- Weight Stability: Crucially, the study reported no weight gain, addressing a common concern for patients initiating or adjusting insulin therapy.
The system proved its versatility across a broad spectrum of clinical needs. Dr. Ly noted that participants required vastly different amounts of insulin, ranging from as little as 10 units per day to as high as 150 units. Because the system is optimized for Type 2 patients—a demographic where the physiology and risks differ from those with Type 1—the algorithm is tuned to minimize hypoglycemia risk, allowing for more aggressive glucose management without the usual fears associated with intensive insulin therapy.
Omnipod 6: Bridging the Gap
While the fully closed-loop system for Type 2 diabetes is the long-term goal, Insulet is also preparing for the near-term rollout of the Omnipod 6. This system, designed for both Type 1 and Type 2 users, represents an evolution of the existing Omnipod 5 platform.
Technological Enhancements:
- Lower Glucose Targets: The Omnipod 6 allows for a target glucose level of 100 mg/dL, enabling tighter glycemic control than its predecessor.
- Enhanced Algorithm: The system features an upgraded algorithm capable of delivering up to 50% more insulin in specific scenarios, providing better coverage for meals and physiological stressors.
- Connectivity and Hardware: The device features improved Bluetooth connectivity, granting patients more flexibility in wear locations. Furthermore, the system will support over-the-air (OTA) updates, a major advancement that allows users to receive software improvements without needing to replace their hardware.
Clinical Findings for Omnipod 6:
In a pivotal study of 132 patients who cycled between the Omnipod 5 and Omnipod 6, the results were promising. For those with Type 1 diabetes, Time in Range improved from 73% to 77%. Type 2 users saw an improvement from 73% to 76%. In a "bolus optional" phase, users maintained similar glycemic outcomes even when reducing their manual boluses to three or fewer per day.
While Insulet continues to recommend that users manually bolus for large meals, the data suggests the Omnipod 6 algorithm is increasingly capable of offsetting smaller mealtime spikes automatically. Insulet plans to submit the Omnipod 6 to the FDA this year, with a market launch expected in 2025.
Implications for the Future of Diabetes Care
The implications of Insulet’s dual-pronged strategy—the near-term refinement of the Omnipod 6 and the long-term "fully closed-loop" system—are profound.
Reducing the "Burden of Care"
For many patients, the primary barrier to effective insulin management is not the availability of the drug, but the complexity of the regimen. By automating titration and eliminating the need for manual bolusing, Insulet is attempting to solve the "human factor" in diabetes care. If patients can achieve clinical-grade outcomes with zero active intervention, the potential for better population-level health outcomes is immense.
The Shift Toward Precision Medicine
Insulet’s system, which requires no initial programming, is a leap toward "plug-and-play" medicine. By standardizing the starting point and allowing the algorithm to learn the patient’s unique insulin sensitivity over time, the company is effectively decentralizing the expertise required to start insulin therapy. This could move care away from specialized endocrinology clinics and into primary care settings, where the vast majority of Type 2 patients are treated.
Competitive Dynamics
The diabetes tech market is currently dominated by high-tech, user-involved systems. By focusing on a "set it and forget it" model, Insulet is carving out a niche that prioritizes simplicity over granular control. As Dr. Ly summarized: "It’s all about doing more for the user, so that they can worry less about diabetes."
As Insulet moves toward the 2025 Evolve trial readout and the subsequent 2028 launch, the medical community will be watching closely. If the results hold, the "no-button" insulin delivery system may well become the new standard of care, fundamentally altering the lives of millions who struggle to keep their blood sugar in check.
